Bamco Inc. NY Takes Position in Kymera Therapeutics, Inc. $KYMR

Bamco Inc. NY purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 7,000 shares of the company’s stock, valued at approximately $396,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Federated Hermes Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth $31,622,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kymera Therapeutics by 77.2% in the second quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after purchasing an additional 10,052 shares during the period. Candriam S.C.A. lifted its stake in shares of Kymera Therapeutics by 24.4% in the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after purchasing an additional 37,536 shares during the period. Frontier Capital Management Co. LLC boosted its holdings in Kymera Therapeutics by 272.7% during the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Kymera Therapeutics by 26.3% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after buying an additional 22,392 shares in the last quarter.

Kymera Therapeutics Trading Up 0.7%

NASDAQ:KYMR opened at $79.60 on Tuesday. The company has a market capitalization of $6.50 billion, a P/E ratio of -21.63 and a beta of 2.20. The firm has a 50-day moving average price of $79.36 and a two-hundred day moving average price of $68.77. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period last year, the company earned ($0.88) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KYMR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. HC Wainwright boosted their price target on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. BTIG Research lowered their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Citigroup raised their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $123.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $118.90.

Insider Activity

In related news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. The trade was a 4.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bruce Booth sold 81,866 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the sale, the director directly owned 675,341 shares in the company, valued at approximately $60,868,484.33. The trade was a 10.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 196,561 shares of company stock worth $17,097,428. 16.01% of the stock is owned by corporate insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.